Abstract. Background/Aim: Sorafenib is standard treatment for advanced hepatocellular carcinoma (HCC). Hand–foot skin reaction (HFSR) is a notorious side-effect of this therapy. This study evaluated prophylactic benefits of an oral nutritional supplement (ONS) on sorafenib-associated HFSR in advanced HCC. Patients and Methods: This was a prospective, single-center, open-label trial arm using combined ONS and sorafenib in patients with unresectable HCC from August 2014 to February 2018. Control patients received sorafenib without ONS from 2011 to 2014. From September 2014, prophylactic ONS containing β-hydroxy-β-methylbutyrate (HMB), L-arginine, and L-glutamine was given. Sorafenib dosage was 400 mg/day for both groups. Results: Each group comprised 22 men and three women. Age, sex, Child-Pugh score, and clinical stage excluding IV-B did not significantly differ between the groups. HFSR occurred after 2 weeks: 15/25 patients in the control group (60%; HFSR grade 1: 6, grade 2: 7, grade 3: 2) vs. 8/25 in the ONS group (32%; HFSR grade 1: 4, grade 2: 4, grade 3: 0; p=0.047, Pearson’s Chi-square test). Conclusion: Prophylactic HMB, L-arginine and L-glutamine supplementation effectively prevented sorafenib-associated HFSR in patients with advanced HCC.

This article is freely accessible online.

Correspondence to: Atsushi Naganuma, Department of Gastroenterology, Takasaki General Medical Center, National Hospital Organization, Takasaki, Japan; Tel: +81 273225901, Fax: +81 273271826, e-mail: naganuma2000@gmail.com

Key Words: Sorafenib, hand–foot skin reaction, β-hydroxy-β-methylbutyrate acid, L-arginine, L-glutamine.
comprising HMB, L-arginine, and L-glutamine on sorafenib-associated HFSR in patients with advanced HCC.

Patients and Methods

Study design. This study compared data obtained in a prospective study with data obtained from historical controls. The prospective, single-center, open-label trial arm using combined ONS and sorafenib involved patients diagnosed with unresectable HCC according to the Barcelona Clinic Liver Cancer Criteria (or the Japan Liver Cancer Study Group Criteria) from August 2014 to February 2018 (5, 6). Patients treated with sorafenib without ONS from January 2011 to July 2014 were enrolled as historical controls and clinical information was collected retrospectively from their electronic medical records. The primary endpoint was incidence of any grade HFSR within 12 weeks of starting sorafenib. Secondary endpoints included time to first occurrence of HFSR, duration of HFSR, percentage of patients with sorafenib dose reduction and interruption or discontinuation, tumor response according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria (7), overall survival (OS), ONS toxicity, and ONS adherence. The HFSR evaluable population comprised all patients who received at least one dose of sorafenib. The efficacy population comprised all patients who received at least one dose of sorafenib and had computed tomographic (CT) scans or magnetic resonance imaging (MRI) available for tumor assessment.

This study was registered in the Clinical Trials Registry of the Japan National University Hospital Medical Information Network (UMIN) on August 27, 2014 (registration ID: UMIN000014953).

Eligibility criteria. The inclusion criteria were as follows: age ≥20 years; HCC diagnosed histologically or clinically (e.g., angiography, CT, and MRI); no indications for hepatectomy or percutaneous radiofrequency ablation; Child–Pugh class A or B; clinical stage II, III, or IV; sufficient organ function; a white blood cell count of ≥3000 cells/μl; platelet count of ≥5.0×10^9/μl; serum total bilirubin <3.0 mg/dl; and Eastern Cooperative Oncology Group performance status of 0–2. Clinical staging of HCC was determined using the Japanese Liver Cancer Study Group (JLCSG) system (5). Exclusion criteria were renal failure (estimated glomerular filtration rate <15 ml/min/1.73 m² or requiring dialysis), previous myocardial infarction or arrhythmia requiring treatment, active concomitant advanced cancer, and refractory ascites or pleural effusion.

Efficacy and safety evaluation. HFSR and all other adverse events (AEs) were evaluated by the treating physician and expert nurse using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (CTCAE v4.0) (8). HFSR was graded as follows: grade 1 (mild): minimal skin changes or dermatitis (erythema) without pain; grade 2 (moderate): skin changes (peeling, blisters, bleeding, edema) or pain, not interfering with function; and grade 3 (severe): ulcerative dermatitis or skin changes with pain interfering with function. Patients in the ONS group were examined for AEs every 2 weeks up to 12 weeks. ONS adherence was also checked at every hospital visit.

Response to sorafenib treatment was evaluated using the mRECIST guidelines (7). Clinical images were obtained using dynamic CT or MRI every 2 months in general. OS was calculated as the period from the date that sorafenib therapy was initiated to the date of death, or until May 2018 for surviving patients.

Treatment method. Clinical indications for HCC treatment using sorafenib were based on the 2013 Clinical Practice Guidelines for HCC of the Japan Society of Hepatology (9). Sorafenib was started for advanced HCC in our hospital in 2009. Because serious AEs were encountered, such as hepatic coma or highly elevated alanineaminotransferase level, upon starting sorafenib therapy (800 mg/day), the initial sorafenib dose was unified to 400 mg/day in patients with HCC. Once HFS management had been mastered, from 2011 to 2014 the control group included patients treated with sorafenib but who did not receive ONS. In September 2014, the administration of orange-flavored prophylactic ONS, Abound™ (Abbott Nutrition, Lake Forest, IL, USA), to sorafenib-treated patients was started. One pack of Abound™ contains HMB (1.2 g/pack), L-arginine, (7 g/pack), and L-glutamine (7 g/pack), and 79 kcal per 24 g. Abound™ was purchased with our hospital’s research funding. In general, patients took one pack of Abound™ daily for ≥3 months. Nutritional guidance was given by registered dietitians to all patients with HCC in order to maintain a good general condition, with reference to the 2012 guidelines of the Japanese Nutritional Study Group for Liver Cirrhosis (10).

All patients received the following basic treatment to prevent HFSR. Prior to sorafenib treatment, patient education (review of HFSR signs and symptoms, including onset and duration) was provided by our healthcare team comprising a trained doctor, nurse, and pharmacist. All patients and their relatives were required to record signs and symptoms daily, and the value and importance of daily skin care to patients was emphasized. All patients were taught daily skin care, which involved the application of 10% urea-based cream three times daily on the hands and feet to soften hyperkeratosis and reduce epidermal thickness. For ongoing patient education, the daily skin care regimen was reinforced and regular scheduled follow-up conducted to assess the skin, particularly in the first 2 weeks to 3 months of sorafenib treatment. Living habits were also guided by requiring patients to wear thick cotton socks and comfortable supportive shoes to protect the feet, cotton gloves to protect the hands and rubber gloves when washing dishes, and to avoid hot water. When grade 1 HFSR occurred, patients were followed-up at least every 2 weeks and a strong steroid (0.05% difluprednate) was used for the affected areas. Changes in the dosing of sorafenib were not recommended. When grade 2 HFSR occurred, anti-inflammatory agents were used (e.g. 60 mg loxoprofen every 8 h, with food) for symptomatic relief. The goal was to bring HFSR to grade 0 or 1 toxicity. Dose reduction of sorafenib to 200 mg daily was recommended until HFSR resolved. If toxicity did not resolve to grade 0 or 1 HFSR, sorafenib was interrupted until HFSR had resolved. When grade 3 HFSR occurred, sorafenib was interrupted until HFSR had resolved. After resuming sorafenib at a reduced dose (200 mg), the dose was increased to 400 mg if HFSR remained at grade 0 or 1.

Statistical analysis. Student’s t-test was used to compare the mean of each variable between the two groups. The Mann–Whitney U-test was used to compare the median of each variable. Categorical data were compared using Pearson’s chi-squared test and Fisher’s exact test. Survival was evaluated using the Kaplan–Meier method, with differences examined using the log-rank test. A p-value less than 0.05 was considered significant. All statistical analyses were performed using the IBM Statistical Package for the Social Sciences software version 21 (IBM Corporation, Armonk, NY, USA).
Results

Patient characteristics. In total, 59 patients with HCC were treated using sorafenib at our hospital from January 2011 to July 2014; these were candidate patients from the historical control arm. After excluding 34 patients on doses other than 400 mg/day sorafenib, 25 patients were enrolled in the control group. Between August 2014 and February 2018, 28 patients with HCC were enrolled in the prospective study arm. It was not possible to evaluate three of these patients because they were lost to follow-up, leaving 25 patients for analysis in the ONS group (Figure 1).

The control group and ONS group each comprised 22 men and three women. Table I shows a comparison of the background characteristics between the two groups. Neither group showed significant differences in terms of sex, age, etiology, clinical stage excluding IV-B using the Japanese Liver Cancer Study Group classification system, Child-Pugh score, or alpha-fetoprotein level. All patients with HCC started sorafenib treatment at 400 mg/day.

Evaluation of HFSR and other adverse effects. Table II shows the occurrence of sorafenib-associated AEs of any grade. The control group had significantly more cases of HFSR than the ONS group \[n=15 (60\%) \text{ vs. } n=8 (32\%), \text{ respectively; } p=0.047\] as well as significantly more cases of diarrhea \[n=14 (56\%) \text{ vs. } n=7 (28\%), \text{ respectively; } p=0.045\]. There were no significant between-group differences in the occurrence of rash, fatigue, alopecia, anorexia, hypertension, headache, dry skin, or erythema.

Figure 2 shows the HFSR grades in the control and ONS groups. HFSR developed in 15 out of 25 patients in the control group but in eight out of 25 patients in the ONS group.

Table I. Patient background characteristics.

|                          | Control group | ONS group | p-Value |
|--------------------------|---------------|-----------|---------|
| Gender, n                |               |           |         |
| Male:female              | 22:3          | 22:3      | >0.99*  |
| Age, years Mean±SD (range) | 68±7.6 (51-87) | 72±12.1 (34-85) | 0.146†  |
| Etiology, n              |               |           |         |
| HCV                      | 13            | 11        | 0.571*  |
| Alcohol                  | 5             | 4         | 0.713*  |
| HBV                      | 2             | 3         | 0.637*  |
| Other                    | 5             | 7         | 0.508*  |
| Clinical stage, n        |               |           |         |
| II                       | 2             | 4         | 0.384*  |
| III                      | 9             | 14        | 0.156*  |
| IV-A                     | 3             | 3         | >0.99*  |
| IV-B                     | 11            | 4         | 0.031*  |
| Child-Pugh grade, n      |               |           |         |
| A                        | 23            | 24        | 0.552*  |
| B                        | 2             | 1         | 0.552*  |
| C                        | 0             | 0         | >0.99*  |
| AFP, ng/ml               | Median (range) | 94.7 (2.8-104,410) | 28.1 (3.6-39,003) | 0.090‡ |

SD: Standard deviation; ONS: oral nutritional supplement; AFP: alpha-fetoprotein; HCV: hepatitis C virus; HBV: hepatitis B virus. Ranges are shown in parentheses. *Pearson’s chi-squared test, †Student’s t-test, ‡Mann–Whitney U-test.

Figure 1. Study design. HFSR: Hand–foot skin reaction; ONS: oral nutritional supplement.
group \((p=0.047)\). Figure 3 shows the prevalence rates of HFSR of any grade at each visit. HFSR occurred after about 2 weeks in both groups, with a significant difference in HFSR prevalence after 4 weeks \((p=0.009)\). Prevalence was lower in the ONS group than the control group at all visits.

Over the study period, 12 out of 25 patients in the control group required dose reduction \((n=3)\) or discontinuation \((n=9)\) of sorafenib due to AEs, with discontinuation required because of disease progression in another 13 patients; only one patient discontinued sorafenib due to HFSR. In the ONS group, 14 out of 25 patients required dose reduction \((n=5)\) or discontinuation \((n=9)\) of sorafenib due to AEs, with discontinuation needed in another 11 patients due to disease progression; two patients discontinued sorafenib due to HFSR.

ONS adherence was good by most patients, except for one who was only able to take half the pack due to the unpleasant taste. No other side-effects due to ONS were noted.

### Responses to and outcomes of sorafenib treatment.

The overall response rate was 8\% \((2/25)\) in both groups. Disease control rates were 56\% \((14/25)\) and 60\% \((15/25)\) in the control and ONS groups, respectively \((p=0.775)\). Median survival time (MST) did not differ significantly between the groups \((p=0.532;\ Figure 4)\). In the control group, 22 out of the 25 patients died of tumor progression and hepatic failure, and MST was 12.0 months, with 1-and 2-year survival rates of 48\% and 32\%, respectively. In the ONS group, 17 out of the 25 patients died of tumor progression and hepatic failure.
and MST was 13.9 months, with 1- and 2-year survival rates of 52.4% and 14%, respectively.

Discussion

HFSR is a very common side-effect in patients treated with sorafenib and affects the treatment schedule and quality of life (1). Successful management of HFSR depends on a strong partnership between the multidisciplinary healthcare team and the patient. Prompt intervention is advised in HFSR because early symptoms can be resolved quickly with minimum effort (11). Ren et al. (12) reported a phase II study that described the prophylactic effect of urea-based cream on HFSR in HCC and the reduced severity of HFSR through basic support (patient education, proactive management, and early detection). However, no standard of care has yet been adopted in patients with HCC treated using sorafenib.

For prevention of HFSR, in this study we focused on HMB L-arginine and L-glutamine as nutritional components that promote collagen synthesis (13). HMB is a naturally-occurring metabolite of the essential amino acid leucine. Several recent studies have hypothesized that HMB is the bioactive metabolite of leucine, responsible for inhibiting muscle proteolysis and modulating protein turnover in vitro and in vivo (14, 15). HMB has been reported to promote protein synthesis via the mammalian target of rapamycin pathway involved in cell division and growth (16), to suppress degradation of body proteins by suppressing the ubiquitin-proteasome system, an intracellular protein degradation pathway (17), and to regulate excessive inflammatory response (18). L-Arginine, and L-glutamine are necessary for wound healing and serve to promote collagen synthesis (13). L-Arginine is a dietary semi-essential amino acid that becomes conditionally dispensable during critical illness and severe trauma (19). Dietary L-arginine supplementation, above the amounts required for optimal growth, nitrogen balance, or health, increases wound collagen accumulation in healthy humans (20). In a clinical report on cancer treatment, supplementation with HMB, L-arginine and L-glutamine was potentially effective in the prevention of radiation dermatitis in patients with head and neck cancer (21). Matsuhashi et al. reported that such supplementation was apparently effective in the treatment of anti-epidermal growth factor receptor antibody-associated skin disorder (22). Yokota et al. conducted a phase II study that showed the efficacy of HMB, L-arginine and L-glutamine supplementation for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer (23). These findings would suggest a preventive effect of HMB, L-arginine and L-glutamine against HFSR in patients with HCC treated with sorafenib. However, the molecular
mechanisms accounting for sorafenib-induced HFSR in these patients remain to be elucidated.

Analysis of sorafenib-associated AEs showed a significant prevention of HFSR in the ONS group compared to the control group in the present study. Interestingly, diarrhea was also significantly reduced in the ONS group (Table II). Several reports have shown that glutamine can contribute to improving the toxic effects of chemotherapy, such as diarrhea, constipation, and nausea (24, 25), and therefore it seems reasonable that HMB, L-arginine and L-glutamine supplementation can also be preventive against sorafenib-induced diarrhea.

Wang et al. described HFSR as a useful indicator in patients with HCC receiving sorafenib therapy (26). In our study, an inhibitory effect of HFSR was obtained in the ONS group. However, there was no difference in OS between the ONS and control groups (Figure 4). Although details underlying this phenomenon are unknown, ONS may be useful in preventing negative effects on OS.

This study is limited by the fact that it involved historical controls. It is possible that AEs may have been missed in this control group if descriptions in the medical charts were inadequate. Accurate evaluation of the benefit of HMB, L-arginine and L-glutamine supplementation against HFSR will require a double-blind randomized controlled trial involving a larger number of patients.

In conclusion, prophylactic supplementation with HMB, L-arginine and L-glutamine was effective in preventing sorafenib-associated HFSR in advanced HCC when combined with basic treatment and patient education about HFSR. However, no survival benefit was observed in patients receiving such supplementation. Randomized controlled trials will be necessary for accurate evaluation of such supplementation against HFSR.

Acknowledgements

The Authors would like to thank Mrs. Hideyo Mashimo and Mrs. Noriko Ozawa for their excellent technical assistance.

References

1. Walko CM and Grande C: Management of common adverse events in patients treated with sorafenib: Nurse and pharmacist perspective. Semin Oncol 41(Suppl 2): S17-S28, 2014.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Grelten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Volutis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390, 2008.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burck K, Zou J, Volutis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1): 25-34, 2009.
4. Fujii C, Imamura H, Fukunaga M, Kamigaki S, Kimura Y, Kawase T, Kabawata R, Fujino M, Iseki C, Hamaguchi Y, Yamamoto E, Ishizaka T and Hachino Y: Efficacy of AboundTM for hand–foot syndrome caused by capecitabine. Gan to Kagaku Ryoho 40(12): 2457-2459, 2013.
5. Izumi N: Diagnostic and treatment algorithm of the Japanese Society of Hepatology: A consensus-based practice guideline. Oncology 78(Suppl 1): 78-86, 2010.
6. Forner A, Reig ME, de Lope CR and Bruix J: Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30(1): 61-74, 2010.
7. Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1): 52-60, 2010.
8. National Institutes of Health, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [Internet]. Bethesda, MD, National Institutes of Health, National Cancer Institute, 2018. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/etc.htm (Last accessed October 6, 2018).
9. Japan Society of Hepatology: Clinical Practice Guidelines for Hepatocellular Carcinoma 2013 (Internet). Tokyo, Japan, Japan Society of Hepatology, 2013. Available from: https://www.jsrh.or.jp/English/guidelines_en/Guidelines_for_hepatocellular_carcinoma_2013 (Last accessed October 6, 2018).
10. Suzuki K, Endo R, Kohgo Y, Ohtake T, Ueno Y, Kato A, Suzuki K, Shiraki R, Moriwaki H, Habu D, Saito M, Nishiguchi S, Katayama K and Sakaida I: Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma. Hepatol Res 42(7): 621-626, 2012.
11. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart I, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L and Dutcher JP: Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9): 1001-1011, 2008.
12 Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, Song T, Zhou W, Wang H, Yang W, Wang X, Yang Y, Shi L, Bai Y, Guo X and Ye SL: Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33(8): 894-900, 2015.

13 Williams JZ, Abumrad N and Barbul A: Effect of a specialized amino acid mixture on human collagen deposition. Ann Surg 236(3): 369-375, 2002.

14 Papet I, Ostaszewski P, Glomot F, Obled C, Faure M, Bayle G, Nissen S, Arnal M and Grizard J: The effect of a high dose of 3-hydroxy-3-methylbutyrate on protein metabolism in growing lambs. Br J Nutr 77(6): 885-896, 1997.

15 Holecek M, Muthny T, Kovarik M and Sispera L: Effect of beta-hydroxy-beta-methylbutyrate on protein metabolism in whole body and in selected tissues. Food Chem Toxicol 47(1): 255-259, 2009.

16 Eley HL, Russell ST, Baxter JH, Mukerji P and Tisdale MJ: Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to catabolic stimuli. Am J Physiol Endocrinol Metab 293(4): E923-E931, 2007.

17 Smith HJ, Mukerji P and Tisdale MJ: Attenuation of proteasome-induced proteolysis in skeletal muscle by beta-hydroxy-beta-methylbutyrate in cancer-induced muscle loss. Cancer Res 65(1): 277-283, 2005.

18 Hsieh LC, Chien SL, Huang MS, Tseng HF and Chang CK: Anti-inflammatory and anticitotoxic effects of short-term beta-hydroxy-beta-methylbutyrate supplementation on chronic obstructive pulmonary disease patients in intensive care unit. Asia Pac J Clin Nutr 15(4): 544-550, 2006.

19 Seifter E, Rettura G, Barbul A and Levenson SM: Arginine: an essential amino acid for injured rats. Surgery 84(2): 224-230, 1978.

20 Barbul A, Lazarou SA, Efron DT, Wasserkrug HL and Efron G: Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 108(2): 331-337, 1990.

21 Imai T, Matsuura K, Asada Y, Sagai S, Katagiri K, Ishida E, Saito D, Sadayasu R, Wada H and Saijo S: Effect of HMB/Arg/Gln on the prevention of radiation dermatitis in head and neck cancer patients treated with concurrent chemoradiotherapy. Jpn J Clin Oncol 44(5): 422-427, 2014.

22 Matsuhashi N, Takahashi T, Nonaka K, Ichikawa K, Yawata K, Tanahashi T, Imai H, Sasaki Y, Tanaka Y, Okumura N, Yamaguchi K, Osada S and Yoshida K: A case report on efficacy of Abound for anti-EGFR antibody-associated skin disorder in metastatic colon cancer. World J Surg Oncol 12: 35, 2014.

23 Yokota T, Hamauchi S, Yoshida Y, Yurikusa T, Suzuki M, Yamashita A, Ogawa H, Onoe T, Mori K and Onitsuka T: A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer. Support Care Cancer 26(9): 3241-3248, 2018.

24 Serna-Thome G, Castro-Eguiluz D, Fuchs-Tarlovsky V, Sanchez-Lopez M, Delgado-Olives L, Coronel-Martinez J, Molina-Trinidad EM, de la Torre M and Cetina-Perez L: Use of functional foods and oral supplements as adjuvants in cancer treatment. Rev Invest Clin 70(3): 136-146, 2018.

25 Jofaie NR, Mirzaie S, Ghasvand R, Askari G and Miraghajani M: The effect of glutamine intake on complications of colorectal and colon cancer treatment: A systematic review. J Res Med Sci 20(9): 910-918, 2015.

26 Wang P, Tan G, Zhu M, Li W, Zhai B and Sun X: Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 12(1): 1-8, 2018.